A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making

    September 2025 in “ Value in Health ”
    Jonathan Mauer, Chiara Whichello, Brett Hauber … Tommi Tervonen
    Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

    We don't know much about this study yet.

    Read the full study on valueinhealthjournal.com →
    Discuss this study in the Community →

    Research cited in this study 9

    1. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
    2. Treatment Preferences of Adults and Adolescents with Alopecia Areata: A Discrete Choice Experiment Journal of dermatology · 2023
    3. Comorbid Conditions Associated With Alopecia Areata: A Systematic Review and Meta-Analysis American Journal of Clinical Dermatology · 2023
    4. Janus Kinase Inhibitors For Alopecia Areata JAMA network open · 2023
    5. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    6. Alopecia Areata and Risk of Common Infections: A Population-Based Cohort Study Clinical and Experimental Dermatology · 2022
    7. Shared Decision-Making, Therapeutic Choice, and Decisional Regret in Patients With Alopecia Areata JAMA Dermatology · 2022
    8. JAK Inhibitors and Alopecia Areata Lancet · 2019
    9. Alopecia Areata: An Autoimmune Disease Causing Hair Loss The New England Journal of Medicine · 2012